AMBELVIST SOLUTION FOR INJECTION IN PREFILLED SYRINGE 0.1MMOL/ML [SIN17632P]
Active ingredients: GADOQUATRANE
Product Info
AMBELVIST SOLUTION FOR INJECTION IN PREFILLED SYRINGE 0.1MMOL/ML
[SIN17632P]
Product information
Active Ingredient and Strength | GADOQUATRANE - 0.1 MMOL/ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | BAYER AG - GERMANY |
Registration Number | SIN17632P |
Licence Holder | BAYER (SOUTH EAST ASIA) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | V08CA13 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Indications
This medicinal product is for diagnostic use only.
Ambelvist is indicated in adults and paediatric patients of all ages including term neonates for contrast enhancement in magnetic resonance imaging (MRI) to detect and visualise known or suspected pathology in the central nervous system (the brain, spine and associated tissues) and body (head and neck, thorax, abdomen, pelvis, extremities).
Dosing
4.2 Dosage and method of administration
4.2.1 Method of administration
This medicinal product is for intravenous administration only.
The intravenous administration should be followed by a flush of 0.9% sodium chloride solution.
After administration, the patient should be kept under observation for at least half an hour, since experience with other gadolinium-based contrast agents (GBCAs) shows that most undesirable effects occur within this time period (see section 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Instructions for use and handling
Visually inspect Ambelvist prior to administration. Do not use the solution if it is discoloured, if particulate matter is present or if the container appears damaged.
Do not mix Ambelvist with other medications because of the potential for chemical incompatibility.
Pre-filled syringes
The pre-filled syringe presentation is for single use only and should be prepared immediately before administration.
4.2.2 Dosage
The dose should be calculated based on the patient’s body weight and should not exceed the recommended dose per kilogram of body weight detailed in this section.
An intravenous injection of 0.1 mL per kg body weight (BW) of Ambelvist is recommended. This is equivalent to 0.01 mmol gadoquatrane per kg body weight or 0.04 mmol gadolinium (Gd) per kg body weight.

4.2.3 Special patient populations
4.2.3.1 Paediatric patients
No dose adjustment is required (see section 5.2 Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Neonates up to 4 weeks of age and infants up to 1 year of age
Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, Ambelvist should only be used in these patients after careful consideration at a dose not exceeding 0.01 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Ambelvist injections should not be repeated unless the interval between injections is at least 7 days.
The safety of gadoquatrane has not been established in preterm neonates.
4.2.3.2 Elderly (aged 65 years and above)
No dose adjustment is required (see section 5.2 Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Caution should be exercised in elderly patients (see section 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
4.2.3.3 Patients with renal impairment
No dose adjustment is required (see section 5.2 Pharmacokinetic properties, Patients with renal impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Ambelvist should only be used in patients with severe renal impairment (GFR< 30 mL/min/1.73m2) and in patients in the perioperative liver transplantation period after careful benefit/risk assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see section 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). If it is necessary to use Ambelvist, the dose should not exceed 0.01 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Ambelvist injections should not be repeated unless the interval between injections is at least 7 days.
Contraindications
4.3 CONTRAINDICATIONS
Hypersensitivity to any of the ingredients.
